» Articles » PMID: 37879897

Are Patients with GBA-Parkinson Disease Good Candidates for Deep Brain Stimulation? A Longitudinal Multicentric Study on a Large Italian Cohort

Abstract

Background: variants increase the risk of developing Parkinson disease (PD) and influence its outcome. Deep brain stimulation (DBS) is a recognised therapeutic option for advanced PD. Data on DBS long-term outcome in carriers are scarce.

Objective: To elucidate the impact of variants on long-term DBS outcome in a large Italian cohort.

Methods: We retrospectively recruited a multicentric Italian DBS-PD cohort and assessed: (1) prevalence; (2) pre-DBS clinical features; and (3) outcomes of motor, cognitive and other non-motor features up to 5 years post-DBS.

Results: We included 365 patients with PD, of whom 73 (20%) carried variants. 5-year follow-up data were available for 173 PD, including 32 mutated subjects. GBA-PD had an earlier onset and were younger at DBS than non-GBA-PD. They also had shorter disease duration, higher occurrence of dyskinesias and orthostatic hypotension symptoms.At post-DBS, both groups showed marked motor improvement, a significant reduction of fluctuations, dyskinesias and impulsive-compulsive disorders (ICD) and low occurrence of most complications. Only cognitive scores worsened significantly faster in GBA-PD after 3 years. Overt dementia was diagnosed in 11% non-GBA-PD and 25% GBA-PD at 5-year follow-up.

Conclusions: Evaluation of long-term impact of variants in a large Italian DBS-PD cohort supported the role of DBS surgery as a valid therapeutic strategy in GBA-PD, with long-term benefit on motor performance and ICD. Despite the selective worsening of cognitive scores since 3 years post-DBS, the majority of GBA-PD had not developed dementia at 5-year follow-up.

Citing Articles

Invasive therapies for Parkinson's disease: an adapted excerpt from the guidelines of the German Society of Neurology.

Reese R, Koeglsperger T, Schrader C, Tonges L, Deuschl G, Kuhn A J Neurol. 2025; 272(3):219.

PMID: 39985674 PMC: 11846738. DOI: 10.1007/s00415-025-12915-6.


Consensus Guidance for Genetic Counseling in GBA1 Variants: A Focus on Parkinson's Disease.

Vieira S, Mezabrovschi R, Toffoli M, Del Pozo S, Menozzi E, Mullin S Mov Disord. 2024; 39(12):2144-2154.

PMID: 39258449 PMC: 11657020. DOI: 10.1002/mds.30006.


Surgicogenomics: The Role of Genetics in Deep Brain Stimulation in Parkinson's Disease Patients.

Kalinderi K, Papaliagkas V, Fidani L Brain Sci. 2024; 14(8).

PMID: 39199492 PMC: 11352397. DOI: 10.3390/brainsci14080800.


Clinical neurophysiology in the treatment of movement disorders: IFCN handbook chapter.

Lefaucheur J, Moro E, Shirota Y, Ugawa Y, Grippe T, Chen R Clin Neurophysiol. 2024; 164:57-99.

PMID: 38852434 PMC: 11418354. DOI: 10.1016/j.clinph.2024.05.007.


Advanced therapies in Parkinson's disease: an individualized approach to their indication.

Schroter N, Sajonz B, Jost W, Rijntjes M, Coenen V, Groppa S J Neural Transm (Vienna). 2024; 131(11):1285-1293.

PMID: 38613674 PMC: 11502575. DOI: 10.1007/s00702-024-02773-3.


References
1.
Mahlknecht P, Foltynie T, Limousin P, Poewe W . How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?. Mov Disord. 2022; 37(8):1581-1592. PMC: 9545904. DOI: 10.1002/mds.29052. View

2.
Pal G, Mangone G, Hill E, Ouyang B, Liu Y, Lythe V . Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers. Ann Neurol. 2022; 91(3):424-435. PMC: 8857042. DOI: 10.1002/ana.26302. View

3.
Krause P, Reimer J, Kaplan J, Borngraber F, Schneider G, Faust K . Deep brain stimulation in Early Onset Parkinson's disease. Front Neurol. 2022; 13:1041449. PMC: 9713840. DOI: 10.3389/fneur.2022.1041449. View

4.
Merola A, Zibetti M, Angrisano S, Rizzi L, Ricchi V, Artusi C . Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients. Brain. 2011; 134(Pt 7):2074-84. DOI: 10.1093/brain/awr121. View

5.
Aybek S, Gronchi-Perrin A, Berney A, Catalano Chiuve S, Villemure J, Burkhard P . Long-term cognitive profile and incidence of dementia after STN-DBS in Parkinson's disease. Mov Disord. 2007; 22(7):974-81. DOI: 10.1002/mds.21478. View